Cortlandt Manor, NY – November 1, 2026 – Polymedco, LLC has been awarded a national group purchasing agreement for National Group Purchasing Agreement with Premier,
Polymedco Announces: New Published Research Supports Fecal Immunochemical Testing (FIT) as the Most Clinically and Cost Effective Noninvasive Colorectal Cancer Screening (CRC) method
Polymedco announces US FDA clearance of the PATHFAST high-sensitivity cardiac troponin I (hs-cTnI-II) test as an aid in the diagnosis of myocardial infarction
Polymedco Joins CancerX to Accelerate Innovation in Cancer Detection and Diagnosis
